Generalized anxiety disorder (GAD) is associated with painful physical symptoms (PPS). These post hoc analyses of previous trial data assessed PPS and their response to duloxetine treatment in GAD patients. Studies 1 and 2 (n = 840) were 9- to 10-week efficacy trials; study 3 (n = 887) was a relapse prevention trial comprising a 26-week open-label treatment phase and a 26-week double-blind, placebo-controlled treatment continuation phase. Mean baseline visual analog scale scores (VAS, 0–100; n = 1727) ranged from 26 to 37 for overall pain, headache, back pain, shoulder pain, interference with daily activities, and time in pain while awake. In studies 1 and 2, improvement on all VAS scores was greater in duloxetine-treated than in placebo-treated patients (p ≤ 0.01). In study 3, pain symptoms worsened in responders switched to placebo compared with those maintained on duloxetine (p ≤ 0.02). In conclusion, duloxetine was efficacious in the short- and long-term treatment of PPS, which are common in GAD patients.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:26856 |
| Date | January 2009 |
| Creators | Beesdo, Katja, Hartford, James, Russell, James, Spann, Melissa, Ball, Susan, Wittchen, Hans-Ulrich |
| Publisher | Technische Universität Dresden |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Source | Journal of Anxiety Disorders, Bd. 23 (2009), Nr. 8, S. 1064–1071, ISSN: 0887-6185 |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 10.1016/j.janxdis.2009.07.008 |
Page generated in 0.0169 seconds